Table 2.
Multivariable Model Assessing Predictors of GI Symptoms in COVID-19–Positive Patients (n = 2804)
| Odds ratio | 95% Confidence interval | P value | |
|---|---|---|---|
| Age | |||
| 18–39 y | (Reference) | — | |
| 40–59 y | 1.14 | 0.88–1.48 | .31 |
| 60–74 y | 0.87 | 0.68–1.12 | .29 |
| 75+ y | 0.59 | 0.45–0.77 | <.01 |
| Male | 0.87 | 0.74–1.01 | .08 |
| BMI | |||
| <18 kg/m2 | (Reference) | — | |
| 18–25 kg/m2 | 0.91 | 0.48–1.74 | .78 |
| 25–30 kg/m2 | 1.23 | 0.65–2.32 | .53 |
| >30 kg/m2 | 1.17 | 0.62–2.22 | .63 |
| Unknown | 0.80 | 0.42–1.51 | .49 |
|
Modified Charlson comorbidity score |
|||
| 0 | (Reference) | – | |
| 1 | 1.11 | 0.91–1.35 | .31 |
| 2+ | 1.22 | 1.01–1.48 | .04 |
| Concomitant GI diseasea | 3.04 | 1.71–5.43 | <.01 |
BMI, body mass index; COVID-19, coronavirus disease 2019; GI, gastrointestinal.
a
Concomitant GI disease includes diverticular disease, irritable bowel syndrome, and inflammatory bowel disease.